Generic Name and Formulations:
Potassium (as chloride) 25mEq; effervescent tabs for soln; citrus and fruit-punch flavor.
Indications for K-LYTE/CL:
Hypokalemia, including that caused by diuretics. Digitalis intoxication without AV block.
Prophylaxis: 25mEq daily. Treatment: 50–100mEq daily in divided doses. Both, dissolve each tab in 6–8oz of water and sip slowly over 5–10 minutes after meals.
Hyperkalemia. Chronic renal disease. Acute dehydration. Heat cramps. Severe tissue destruction. Adrenal insufficiency. Familial periodic paralysis. Acidosis (potassium chloride products). Alkalosis (potassium bicarbonate products). Tablets: Esophageal compression due to enlarged left atrium. Decreased GI motility.
Discontinue if GI bleed, ulceration, or other disturbances occur. Renal or cardiac disease. Monitor potassium level, clinical status, acid-base balance, and ECG. Elderly. Pregnancy (Cat.C). Nursing mothers.
Hyperkalemia with ACE inhibitors, spironolactone, triamterene, amiloride, and potassium-containing salt substitutes. Anticholinergics, other agents that decrease GI motility increase risk of serious GI reactions with tablets.
Hyperkalemia, GI discomfort and irritation, diarrhea, rash (rare). Tablets: Esophageal and GI ulceration, bleeding, obstruction, perforation.
K-Lyte/Cl tabs—30, 100, 250; K-Lyte/Cl 50 tabs—30, 100
Neurology Advisor Articles
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Serious Adverse Events Profile for Cladribine Confirmed With Extended Data
- Patients With Multiple Sclerosis Face Greater Infection Risk
- Ozanimod Reduces Severe Relapses in Multiple Sclerosis More Than Interferon Beta-1a